PX-478 is a selective inhibitor that suppresses constitutive and hypoxia-induced HIF-1α levels. PX-478 inhibits HIF-1α at multiple levels including inhibition of HIF-1α translation and reduction in HIF-1α mRNA levels.[1] PX-478 also has been shown antitumor activity against several aggressive human tumor xenografts.[2]
In vitro and in vivo study demonstrated that PX-478 could inhibit normoxic and hypoxia-induced HIF-1α expression as well as inflammatory molecule COX-2 and immunosuppressive molecule PD-L1 expression. Therefore, PX-478 shows a wide effect on tumor development, such as suppressing proliferation, promoting cells apoptosis, inhibiting EMT process and arresting cell cycle. In vivo experiment indicated the inhibitory effect of PX-478 on tumor growth. [1]
References:
[1].Zhu Y, et al. Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo. Am J Cancer Res. 2017 May 1;7(5):1198-1212.
[2].Palayoor ST, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008 Nov 15;123(10):2430-7.
PX-478是一种选择性抑制剂,可以抑制常规和低氧诱导的HIF-1α水平。PX-478在多个层面上抑制HIF-1α,包括抑制HIF-1α翻译和降低HIF-1α mRNA水平。[1]此外,PX-478还显示出对几种侵袭性人类肿瘤异种移植的抗肿瘤活性。[2]
体外和体内研究表明,PX-478可以抑制正常氧和低氧诱导的HIF-1α表达以及炎性分子COX-2和免疫抑制分子PD-L1的表达。因此,PX-478对肿瘤发展具有广泛影响,如抑制增殖、促进细胞凋亡、抑制EMT过程并阻止细胞周期。体内实验显示了PX-478对肿瘤生长的抑制作用。[1]
















